The ARRB2 Knockout HAP1 Polyclonal Cells constitute a polyclonal knockout cell population generated by CRISPR/Cas9-mediated disruption of the ARRB2 gene in the HAP1 cell background. This product provides a heterogeneous pool of edited cells, enabling robust and reproducible loss-of-function analysis without clonal isolation. The targeted disruption of ARRB2 eliminates expression of the encoded ??-arrestin-2 protein, offering a clean genetic model for investigating arrestin-dependent signaling mechanisms across diverse experimental paradigms.
HAP1 is a near-haploid human fibroblast-like cell line originally derived from the KBM-7 chronic myeloid leukemia line, which is BCR-ABL positive. The haploid karyotype facilitates straightforward genetic manipulation and phenotype?Cgenotype correlation, making HAP1 a workhorse for functional genomics and haploid genetic screens. Its adherent growth, rapid proliferation, and sensitivity to a wide range of signaling inputs render it particularly suitable for dissecting dynamic cellular pathways such as those governed by G protein-coupled receptors.
ARRB2 encodes ??-arrestin-2, a multifunctional adaptor protein that is crucial for GPCR regulation. Upon agonist stimulation, GPCR kinases (GRKs) phosphorylate activated receptors??including ??2-adrenergic, angiotensin II type 1, and chemokine receptors??promoting ??-arrestin-2 recruitment. This interaction triggers receptor desensitization and clathrin/AP-2-dependent internalization. Beyond its endocytic function, ??-arrestin-2 scaffolds a diverse array of signaling molecules, such as Src family kinases, ERK1/2, JNK, and PI3K, thereby activating G protein-independent pathways. These cascades culminate in the modulation of transcription factors including NF-??B, AP-1, and ??-catenin, linking ??-arrestin-2 to gene expression programs involved in proliferation, inflammation, and survival.
In the HAP1 context, loss of ARRB2 renders cells deficient in ??-arrestin-2-mediated desensitization and scaffolding, thereby permitting direct interrogation of arrestin-dependent versus G protein-dependent signaling routes. The BCR-ABL-positive background further enables studies intersecting oncogenic kinase signaling with GPCR pathways, a combination relevant to leukemogenesis and drug resistance. The polyclonal nature of the knockout population diminishes clone-specific artifacts, ensuring that observed phenotypic changes are attributable to ARRB2 disruption rather than clonal variation, thus strengthening the validity of mechanistic conclusions.
This knockout model is ideally suited for functional dissection of GPCR signaling, particularly ??-arrestin-biased signal transduction, and for validating drug targets that exploit arrestin-mediated pathways. Researchers can employ it in high-throughput screening campaigns to identify modulators of arrestin-dependent ERK, JNK, or NF-??B activation, using assays such as phospho-ERK flow cytometry, BRET-based ??-arrestin recruitment, and NF-??B luciferase reporters. Additional applications include chemokine receptor internalization studies via immunofluorescence and migration/invasion assays to assess metastatic potential. For further technical information, please contact Ascent Research.
